- Tanvex BioPharma, Inc. has successfully acquired Bora Biologics, a subsidiary of Bora Pharmaceuticals, to expand its global biologics CDMO capabilities.
- The acquisition integrates Tanvex’s U.S.-based commercialization expertise with Bora’s biologics development operations in Taiwan.
Tanvex BioPharma, Inc. has announced the completion of its acquisition of Bora Biologics Co., Ltd., a subsidiary of Bora Pharmaceuticals. The combined entity’s CDMO services will operate under the Bora Biologics name while continuing to be owned by Tanvex.
“The completion of this acquisition marks a pivotal moment for Tanvex and Bora Biologics,” said Stephen Lam, Chief Executive Officer of Tanvex. “We are adopting the name Bora Biologics to honour the legacy, reputation, and partnership power of a Bora brand while seamlessly integrating its strengths with our commercialization success in the U.S.”
This acquisition combines Tanvex’s FDA-licensed commercial-scale biosimilar manufacturing in San Diego with Bora Biologics’ early-stage biologics CDMO expertise in Taiwan. The move is designed to offer clients comprehensive, end-to-end biologics solutions, from development to commercial-scale manufacturing, supported by state-of-the-art facilities equipped with multiple 2000 L bioreactors.
Stephen Lam will lead the newly merged organisation, ensuring integration of Bora Biologics’ operations and client-focused approach with Tanvex’s proven development capabilities. The collaboration will also leverage the leadership of Bobby Sheng, Chairman of the Bora Group, who will now serve as Chairman of Tanvex.
Existing contracts and partnerships will remain unaffected by the transition, and Bora Biologics aims to build on its established reputation for quality and innovation. With seamless technical transfer services between Taiwan and the U.S., the organisation is set to empower biopharma companies with efficient and cost-effective pathways to market.
The Tanvex biosimilar product line will continue to operate under the Tanvex brand, maintaining its focus on planned and future commercialisation efforts.